Risperidone and Desipramine in Alcohol Use and Schizophrenia

Completed · Phase 2

Conditions studied: Schizophrenia, Alcoholism, Dual Diagnosis

In brief

Note: In June 2013, the study design was changed from a randomized controlled study of risperidone + despiramine vs. risperidone vs. placebo to an open label pre-post study of risperidone (or risperidone-like drug) + desipramine. The aims of the study were revised to read: 1. To determine whether participants treated with risperidone in combination with desiprmaine have less alcohol use (fewer drinking days; fewer heavy drinking days) during the final 8 weeks on these medications as compared to pre-baseline. The primary hypothesis is that compared to pre-baseline, participants will demonstrate fewer days of drinking (per week), as well as fewer days of heavy drinking (per week) in the final eight weeks they are taking risperidone and desipramine, as recorded on the Timeline Follow-Back assessment 2. To explore changes in symptoms (of schizophrenia and of depression) in the final eight weeks of treatment with risperidone + desipramine compared to the period before baseline 3. To assess the side effect burden associated with the combination of these two medications in participants. The original aims of the study were: The purpose of this study is to determine whether participants who are treated with risperidone in combination with desipramine have less alcohol use (fewer drinking days; fewer heavy drinking days) than do participants who are treated with RISP with placebo. The primary hypothesis is that compared to treatment with risperidone, participants randomized to a combination of risperidone plus desipramine will have fewer days of drinking, as well as fewer days of heavy drinking. The study will also compare the effects of risperidone as compared to risperidone plus desipramine on participants' symptoms and side effects.

Key facts

Study ID

NCT01411085

Run by

Dartmouth-Hitchcock Medical Center

People needed

12

Starts

2011-12-01

Expected to finish

2014-09-01

Last updated by the study team

2018-03-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Meets the diagnostic criteria of schizophrenia or schizoaffective disorder
• Meets the diagnostic criteria for a current alcohol use disorder (abuse or dependence)
• Recent alcohol use as documented on the Timeline Followback
• Receives outpatient treatment with oral antipsychotic medication (including risperidone.
• Is willing to switch to risperidone treatment at the beginning of the study.

You may not qualify if…

• Other substance use disorder other than alcohol, caffeine and nicotine, and cannabis abuse, as defined by DSM-IV criteria.
• Receives current treatment with Clozapine
• Continues to use alcohol despite current adequate treatment with medication to decrease alcohol use(e.g. naltrexone, acamprosate, disulfiram or topiramate)
• Is determined to be a "slow metabolizer" of CYP2D6
• Is currently pregnant, trying to become pregnant, or nursing

Where it is running

• University of Massachusetts Medical School — Worcester, Massachusetts, United States
• Michigan State University / Cherry Street Health Services — Grand Rapids, Michigan, United States
• Dartmouth Medical School — Lebanon, New Hampshire, United States
• University of South Carolina School of Medicine — Columbia, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.